Amneal files pro forma data for Kashiv BioSciences deal
Amneal Pharmaceuticals, Inc. completed its acquisition of Kashiv BioSciences, LLC on August 10, 2026. The Delaware corporation finalized the transaction, which is accounted for as a business combination under U.S. Generally Accepted Accounting Principles (GAAP). Amneal treated itself as the acquirer and Kashiv as the acquired company for financial reporting purposes. The company issued 28.9 million shares of Amneal Class A common stock, with a par value of $0.01 per share, as part of the consideration. Cash consideration was funded through available cash, $350.0 million in incremental borrowings under an existing term loan due 2032, and $180.0 million in additional borrowings under an existing revolving credit facility. Amneal filed unaudited pro forma condensed combined financial information with the U.S. Securities and Exchange Commission (SEC) pursuant to Article 11 of Regulation S-X. The pro forma balance sheet as of June 30, 2026, reflects the combination of Amneal's historical assets and Kashiv's assets after reclassifications and transaction accounting adjustments. The pro forma operating results cover the six-month period ending June 30, 2026, and the fiscal year ending December 31, 2025. These figures assume the deal closed on January 1, 2025. The preliminary purchase price allocation is based on best estimates of fair value and remains subject to adjustment as additional information becomes available. The financial information does not include anticipated synergies, operating efficiencies, or cost savings resulting from the transaction. Amneal’s unaudited interim consolidated financial statements for the six months ended June 30, 2026, were previously filed in a Quarterly Report on Form 10-Q on August 6, 2026. The company's audited annual consolidated financial statements for the fiscal year ended December 31, 2025, were filed in an Annual Report on Form 10-K on February 27, 2026. Kashiv's unaudited interim consolidated financial statements for the six months ended June 30, 2026, are included as Exhibit 99.2 to the Current Report on Form 8-K/A. Kashiv's audited annual consolidated financial statements for the fiscal year ended December 31, 2025, are included as Exhibit 99.1 to the same report.
Amneal Pharmaceuticals, Inc. completed its acquisition of Kashiv BioSciences, LLC on August 10, 2026. The Delaware corporation finalized the transaction, which is accounted for as a business combination under U.S. Generally Accepted Accounting Principles (GAAP). Amneal treated itself as the acquirer and Kashiv as the acquired company for financial reporting purposes. The company issued 28.9 million shares of Amneal Class A common stock, with a par value of $0.01 per share, as part of the consideration. Cash consideration was funded through available cash, $350.0 million in incremental borrowings under an existing term loan due 2032, and $180.0 million in additional borrowings under an existing revolving credit facility. Amneal filed unaudited pro forma condensed combined financial information with the U.S. Securities and Exchange Commission (SEC) pursuant to Article 11 of Regulation S-X. The pro forma balance sheet as of June 30, 2026, reflects the combination of Amneal's historical assets and Kashiv's assets after reclassifications and transaction accounting adjustments. The pro forma operating results cover the six-month period ending June 30, 2026, and the fiscal year ending December 31, 2025. These figures assume the deal closed on January 1, 2025. The preliminary purchase price allocation is based on best estimates of fair value and remains subject to adjustment as additional information becomes available. The financial information does not include anticipated synergies, operating efficiencies, or cost savings resulting from the transaction. Amneal’s unaudited interim consolidated financial statements for the six months ended June 30, 2026, were previously filed in a Quarterly Report on Form 10-Q on August 6, 2026. The company's audited annual consolidated financial statements for the fiscal year ended December 31, 2025, were filed in an Annual Report on Form 10-K on February 27, 2026. Kashiv's unaudited interim consolidated financial statements for the six months ended June 30, 2026, are included as Exhibit 99.2 to the Current Report on Form 8-K/A. Kashiv's audited annual consolidated financial statements for the fiscal year ended December 31, 2025, are included as Exhibit 99.1 to the same report.